Olanzapine - Isotope Labelled Standards
References
FAQ's
References
- Chakrabarti, Jiban Kumar; Hotten, Terrence Michael; Tupper, David Edward, Pharmaceutical compounds, Lilly Industries Ltd., United Kingdom, EP454436B1, September 13, 1995
- Catlow, John T.; Barton, Richard D.; Clemens, Matt; Gillespie, Todd A.; Goodwin, Michael; Swanson, Steven P., Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection, Journal of Chromatography B: Biomedical Sciences and Applications, Volume: 668, Issue: 1, Pages: 85-90,1995
Frequently Asked Questions
How are Olanzapine Impurities controlled?
During manufacturing, strict quality control procedures help manage Olanzapine impurities. Impurity levels are subject to regulatory bodies' limitations.
How are Olanzapine impurities formed?
During the synthetic process of Olanzapine, unintended chemical reactions or side reactions can occur, leading to the formation of impurities. These impurities can result from incomplete reactions, unexpected intermediates, or variations in reaction conditions.
Can Olanzapine Impurities be removed?
During synthesis, Olanzapine impurities are controlled by utilizing established analytical techniques, monitoring reaction conditions, and adopting quality control measures.
What are the temperature conditions required to store Olanzapine Impurities?
Olanzapine impurities are stored at a regulated room temperature of 2-8°C or as specified on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.